<DOC>
	<DOCNO>NCT00329797</DOCNO>
	<brief_summary>RATIONALE : Zoledronate may prevent bone loss patient prostate cancer undergo radiation therapy hormone therapy . It yet know whether zoledronate effective calcium vitamin D alone prevent osteoporosis bone fracture patient prostate cancer . PURPOSE : This randomized phase III trial study zoledronate see well work compare calcium vitamin D alone prevent osteoporosis bone fracture patient locally advance nonmetastatic prostate cancer undergo radiation therapy hormone therapy .</brief_summary>
	<brief_title>Zoledronate Preventing Osteoporosis Bone Fractures Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare potential benefit bisphosphonate therapy comprise zoledronate plus vitamin D calcium supplement v standard therapy vitamin D calcium supplement prevention osteoporosis associate bone fracture patient locally advance nonmetastatic adenocarcinoma prostate undergoing radiotherapy luteinizing hormone-releasing hormone ( LHRH ) agonist therapy . Secondary - Evaluate potential benefit regimen quality life patient . - Evaluate potential benefit bone mineral density period 3 year patient treat regimen . OUTLINE : This randomize multicenter study . Patients stratify accord T score hip dual x-ray absorptiometry ( DXA ) scan ( &lt; -1.0 &gt; -2.5 v ≥ - 1.0 ) plan duration luteinizing hormone-releasing hormone ( LHRH ) agonist therapy ( 1-2½ year vs &gt; 2½ year ) . Patients randomize 1 2 treatment arm . - Arm I : Parents receive zoledronate IV 15 minute every 6 month . Patients also receive oral calcium oral cholecalciferol ( vitamin D ) daily . Treatment continue 3 year absence bone fracture , disease progression , unacceptable toxicity . - Arm II : Patients receive oral calcium oral vitamin D daily . Treatment continue 3 year absence bone fracture , disease progression , unacceptable toxicity . All patient also undergo concurrent radiotherapy ( external beam , brachytherapy , ) LHRH agonist ( e.g. , leuprolide acetate , goserelin , buserelin , triptorelin ) therapy . Quality life assess baseline every 6 month treatment . PROJECTED ACCRUAL : A total 1,272 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Buserelin</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma prostate Diagnosed within past 12 month Any 1 follow clinical stage : Clinical stage T3 , N , M0 Gleason score prostatespecific antigen ( PSA ) Any T , N , M0 one following : Gleason score ≥ 8 PSA Gleason score 7 PSA ≥ 15 ng/mL Gleason score &lt; 7 PSA ≥ 20 ng/mL Baseline T score &gt; 2.5 L spine total hip dual xray absorptiometry ( DXA ) scan Planning receive luteinizing hormonereleasing hormone ( LHRH ) agonist therapy If patient receive LHRH therapy study entry , therapy must begin ≤ 6 month prior study entry Scheduled receive LHRH agonist ≥ 1 year Planning undergo radiotherapy ( i.e. , externalbeam , brachytherapy , ) No distant metastasis Must negative bone scan metastatic disease PATIENT CHARACTERISTICS : Zubrod performance status 01 Creatinine clearance &gt; 30 mL/min Calcium 8.410.6 mg/dL Fertile patient must use effective contraception ≥ 3 month completion study treatment No history Paget 's disease No uncontrolled thyroid parathyroid dysfunction No known hypersensitivity zoledronate bisphosphonates No infection teeth jawbone No dental fixture trauma No current prior diagnosis osteonecrosis jaw No expose bone mouth No slow heal dental procedure No active dental problem No disease influence bone metabolism No malignancy within past 3 year except nonmelanomatous skin cancer carcinoma situ breast oral cavity PRIOR CONCURRENT THERAPY : See Disease Characteristics More 6 week since prior dental jaw surgery ( e.g. , extraction , implant ) No prior bisphosphonate therapy No prior pelvic radiation No prior systemic radiotherapeutic agent , strontium chloride Sr 89 samarium Sm 153 lexidronam pentasodium No concurrent systemic chemotherapy No concurrent steroids No concurrent growth hormones No concurrent calcitonin No concurrent dental jaw surgery</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>